Relmada Therapeutics (RLMD) Competitors $2.01 0.00 (0.00%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$2.03 +0.02 (+1.00%) As of 10/17/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RLMD vs. ZURA, TKNO, AVTE, PBYI, OGI, IMRX, VTYX, PRQR, RENB, and SGMTShould you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include Zura Bio (ZURA), Alpha Teknova (TKNO), Aerovate Therapeutics (AVTE), Puma Biotechnology (PBYI), Organigram Global (OGI), Immuneering (IMRX), Ventyx Biosciences (VTYX), ProQR Therapeutics (PRQR), Lunai Bioworks (RENB), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry. Relmada Therapeutics vs. Its Competitors Zura Bio Alpha Teknova Aerovate Therapeutics Puma Biotechnology Organigram Global Immuneering Ventyx Biosciences ProQR Therapeutics Lunai Bioworks Sagimet Biosciences Zura Bio (NASDAQ:ZURA) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership. Which has more risk and volatility, ZURA or RLMD? Zura Bio has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Does the media prefer ZURA or RLMD? In the previous week, Zura Bio had 6 more articles in the media than Relmada Therapeutics. MarketBeat recorded 6 mentions for Zura Bio and 0 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.30 beat Zura Bio's score of -0.09 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Zura Bio Neutral Relmada Therapeutics Neutral Do analysts prefer ZURA or RLMD? Zura Bio currently has a consensus price target of $11.60, indicating a potential upside of 261.37%. Relmada Therapeutics has a consensus price target of $1.00, indicating a potential downside of 50.25%. Given Zura Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Zura Bio is more favorable than Relmada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zura Bio 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75Relmada Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Do institutionals & insiders hold more shares of ZURA or RLMD? 61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 14.2% of Zura Bio shares are owned by company insiders. Comparatively, 20.7% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation & earnings, ZURA or RLMD? Zura Bio is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZura BioN/AN/A-$45.39M-$0.70-4.59Relmada TherapeuticsN/AN/A-$79.98M-$2.22-0.91 Is ZURA or RLMD more profitable? Zura Bio's return on equity of -49.11% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zura BioN/A -49.11% -40.06% Relmada Therapeutics N/A -223.17%-180.41% SummaryZura Bio beats Relmada Therapeutics on 10 of the 13 factors compared between the two stocks. Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLMD vs. The Competition Export to ExcelMetricRelmada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.72M$2.61B$6.09B$10.49BDividend YieldN/A57.79%5.73%4.80%P/E RatioN/A22.9985.6227.13Price / SalesN/A561.49517.46179.23Price / CashN/A168.7137.2361.22Price / Book1.705.3212.236.52Net Income-$79.98M$33.06M$3.33B$276.93M7 Day Performance-1.47%2.29%1.17%1.93%1 Month Performance21.82%6.32%6.14%2.19%1 Year Performance-44.32%-5.42%59.98%34.99% Relmada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLMDRelmada Therapeutics2.494 of 5 stars$2.01flat$1.00-50.2%-42.4%$66.72MN/A0.0010ZURAZura Bio2.6084 of 5 stars$3.86-7.0%$11.60+200.5%-34.4%$269.83MN/A-5.513News CoverageAnalyst ForecastShort Interest ↑Gap DownTKNOAlpha Teknova1.8619 of 5 stars$5.01+1.0%$10.00+99.6%-18.1%$265.43M$37.74M-11.93240AVTEAerovate TherapeuticsN/A$9.08-3.4%N/A-87.9%$263.18MN/A-3.0420High Trading VolumePBYIPuma Biotechnology3.6171 of 5 stars$5.29+3.3%$7.00+32.3%+93.3%$257.90M$230.50M5.40200OGIOrganigram Global0.9823 of 5 stars$1.92+0.5%N/A+4.6%$256.59M$117.47M38.41860News CoverageIMRXImmuneering3.508 of 5 stars$6.14+0.2%$16.40+167.1%+167.0%$254.83M$320K-3.2560Positive NewsShort Interest ↑VTYXVentyx Biosciences1.3256 of 5 stars$3.71+4.2%$7.50+102.2%+60.0%$253.86MN/A-2.2130PRQRProQR Therapeutics2.3495 of 5 stars$2.29-5.0%$8.00+249.3%-38.1%$253.56M$20.46M-4.98180News CoverageAnalyst DowngradeGap UpRENBLunai Bioworks0.1784 of 5 stars$1.54+21.7%N/A-79.3%$250.24MN/A-2.0020Gap DownSGMTSagimet Biosciences3.4464 of 5 stars$7.60-1.0%$25.67+237.7%+36.3%$249.60M$2M-4.158Analyst Upgrade Related Companies and Tools Related Companies Zura Bio Alternatives Alpha Teknova Alternatives Aerovate Therapeutics Alternatives Puma Biotechnology Alternatives Organigram Global Alternatives Immuneering Alternatives Ventyx Biosciences Alternatives ProQR Therapeutics Alternatives Lunai Bioworks Alternatives Sagimet Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLMD) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThis dark force is about to change everythingSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredElon’s Optimus to mint new “Musk Millionaires” as soon as Oct 23???Elon Musk may be set to create more "Musk Millionaires" as soon as October 23rd… Because on that day, he's exp...InvestorPlace | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
